• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 29th October 2014

OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The first blog is available here). Please feel free to contact any of the OHE…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The first blog is available here). Please feel free to contact any of the OHE team members listed for additional information.

Innovation and value

Conceptual challenges: valuing cures

1.       What Value Do We Place on a Cure? Value Demonstration Challenges Associated with Innovator and Regenerative Therapies in the EU, North America, and Asia.

Moderator: Eric C Faulkner (University of North Carolina, Chapel Hill) Panelists: Adrian Towse (OHE), Don Husereau, University of Ottawa and UMIT, Joshua J. Carlson (VeriTech Corporation) (IP6, 11 Nov, 10:15–11:15)

This panel addresses the implications of assessing the cost-effectiveness of emerging regenerative medicines, including gene therapy “cures”, looking at how payment could be financed and linked to outcomes.

Practical challenges: pricing/reimbursement and innovation

2.       An Introduction to Multi-criteria Decision Analysis in Health Care Decision Making – Emerging Good Practices.

Chair: Maarten J IJzerman, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine.; Speakers: Nancy Devlin (OHE), Praveen Thokala (University of Sheffield) and Kevin Marsh (Evida). (ISPOR Forums Session I, 10 Nov, 18:00-19:00)

This forum will highlight the work being done by the ISPOR Taskforce on emerging good practices in MCDA, which Nancy co-chairs. The objective of the taskforce is to provide a common definition for MCDA in health care decision-making and to develop good practices for conducting MCDA to aid health care decision making. 

For OHE’s primer on MCDA, click here. 

3.       The Expanding Value Footprint of Oncology Treatments.

Juan Carlos Rejon-Parrilla (OHE), Karla Herandez-Villafuerte (OHE), Koonal K Shah (OHE), Jorge Mestre-Ferrandiz (OHE, presenting), Lou Garrison (University of Washington) and Adrian Towse (OHE)

This poster examines the history and importance of HTA evaluations for additional uses for cancer drugs after their initial approval. The cohort of cancer drugs included are the ten approved by the EMA during 2003–2005. The decisions of three entities are included in the study: the Haute Autorité de Santé in France; NICE in England and Wales; and Aetna, a private health insurance company in the US. These three were selected to suggest how assessment approaches might differ in interpreting value. (PCN227, 12 Nov, 08:45–14:45)

For a recent version of the study, click here.

Dealing with uncertainty while enhancing access

4.       Earlier Access to Innovation – Is It worth It?

Moderator: Adrian Towse (OHE), with.Hans-Georg Eichler (EMA), Richard Bergstrom (EFPIA), Carole Longson (NICE), and Alric Reuther (IQWiG).

This plenary will explore whether earlier licensing of products will benefit patients, given the challenges faced by HTA bodies in making assessments with limited evidence. It will address adaptive licensing, coverage with evidence development, and other programs to deal with evidence uncertainty. (Second Plenary, 11 Nov, 13:30–15:00)

5.       Performance-based Risk-sharing Arrangements for Drugs and Other Medical Products.

Adrian Towse (OHE), Lou Garrison (University of Washington) Josh Carlson (University of Washington)

This short course explores the theory and practice behind PBRSAs, including trends, and the challenges involved in putting them in place. Prior registration is required. 8 Nov, 14:00–18:00

Comparative cost effectiveness analysis for a specific condition

6.       A Cost-effectiveness Analysis of Interventions for Symptomatic Varicose Veins.

Grace Marsden (OHE, presenting), Mark Perry (National Clinical Guideline Centre), Andres Bradbury (University of Birmingham), Nicholas Hickey (University of Birmingham), Kate Kelley (National Clinical Guideline Centre), Hazel Trender (Sheffield Teaching Hospital Foundation Trust), David Wonderling  (National Clinical Guideline Centre) and Alun Davies (Imperial College & Imperial College NHS Trust)

This poster reports on an economic analysis that formed part of the NICE clinical guideline on varicose vein treatment and was conducted to investigate whether such treatments should be recommended across the UK. It compared the cost-effectiveness of surgery, endodermal ablation, ultrasound guided foam sclerotherapy and compression stockings using a Markov decision model with a five-year time horizon. (PCV94, 11 Nov, 8:45–13:30)

Health care systems: methods for valuing health states

Methods: instrument design

7.       Valuing EQ-5D-5L: Does the Ordering of the Health Dimensions Impact on Health State Valuations?

Brendan Mulhern (University of Sheffield, presenting) and Koonal K Shah (OHE)

This presentation is based on research intended to explore whether changing the order in which the five health dimensions are presented affects the outcome of the exercise. The analysis is based on face-to-face, computer-assisted interviews with 450 members of the general public. (PR4, 10 Nov, 15:30–16:30)

Methods: eliciting more accurate TTO results

8.       What Is the Appropriate Comparator Health State to Use in Time Trade-off Studies?

Koonal K Shah (OHE, presenting) and Brendan Mulhern (University of Sheffield)

This poster reports findings from a methodological health state valuation study. Studies to produce utility values for the EQ-5D-5L instrument include the valuation of 10 health states using the time trade-off (TTO) method. In some of the studies, relatively low mean TTO values for mild health states have been observed. One hypothesis is that this is because the health states under evaluation are being compared to ‘full health’, whereas in previous studies they were compared to 11111 (the ‘best’ health state in the descriptive system). This poster assesses differences in TTO valuations using these two comparators. It is based on 450 interviews that were completed in mid-2014. (PRM162, 11 Nov, 15:30–19:30)

  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!